Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
8,237 people get TEVA articles and Market Currents by email alert.
Get email alerts on TEVA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
Business Wire (Tue, 10:35AM)
-
-
-
-
-
-
-
-
-
-
Business Wire (May 8, 2013)
-
-
-
-
Business Wire (May 2, 2013)
To learn more about Seeking Alpha Pro, click here.
-
Teva's CEO Reviews Management Succession (Transcript)Tue, Jan 3, 2012
-
Teva CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Feb 8, 2011 • 1 Comment
-
Teva Pharmaceutical Industries Limited Q2 2010 Earnings Call TranscriptTue, Jul 27, 2010 • 1 Comment
-
Business Wire (Tue, 10:35AM)
-
at CNBC.com (May 9, 2013)
-
at CNBC.com (May 8, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 2, 2013)
-
at CNBC.com (Apr 26, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 23, 2013)
-
at CNBC.com (Apr 11, 2013)
-
Business Wire (Apr 9, 2013)
-
Business Wire (Apr 8, 2013)
-
Business Wire (Apr 8, 2013)
TEVA vs. ETF Alternatives
Company Description
Teva Pharmaceutical Industries Limited (“Teva”) is a global pharmaceutical company that develops, produces and markets generic drugs in all major therapeutic categories. We are the leading generic drug company in the world – with the leading position in the U.S. (in terms of both value and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 2, 7:03 AM Teva Pharma (TEVA): Q1 EPS of $1.12 beats by $0.01. Revenue of $4.9B beats by $0.05B. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, February 8, 1:56 PM Teva Pharmaceutical (TEVA +2.3%) shrugs off a downgrade to Hold at Canaccord to trade higher today. The company has been creeping higher since posting a less-than-stellar Q4 earnings report yesterday morning, perhaps in part due to comments during its conference call that sales of its MS drug Copaxone rose by 14% to $1.1B. Read more here: Earnings Call Transcript. Comment! [On the Move, Healthcare, Earnings]
- Thursday, February 7, 9:03 AM More on Teva (TEVA -2.1%) Q4: net profit -37% to $320M as revenue falls 7.5%. U.S. sales -14% to $2.6B amid a sharp fall in Provigil (sleep disorder) due to generic competition. Copaxone global revenues +14% to $1.1B, but faces increasing competition. Expects to launch 23 generic drugs in 2013, as in 2012. Reiterates 2013 revenue forecast of $19.5-20.5B and adjusted EPS of $4.85-5.15. Declares dividend of 1.15 shekels (31 cents) a share, +15% from Q3. 2 Comments [Healthcare, Earnings, Dividends]
- Thursday, February 7, 7:02 AM Teva Pharma (TEVA): Q4 EPS of $1.32 misses by $0.01. Revenue of $5.2B misses by $0.06B. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
- Thursday, February 7, 12:05 AM Notable earnings before Thursday’s open: AAP, ALU, BG, CCE, CI, CS, CTSH, EXC, FLIR, FLO, GPK, HLSS, HOT, INGR, KKR, MFC, MPW, MWW, NBL, NNN, NYT, ONNN, OZM, PM, PMT, PTEN, S, SBH, SIAL, SNE, SNI, SPH, SQNS, TDC, TEVA, XYL Comment! [Earnings]
- Wednesday, February 6, 5:30 PM Notable earnings before Thursday’s open: AAP, ALU, BG, CCE, CI, CS, CTSH, EXC, FLIR, FLO, GPK, HLSS, HOT, INGR, KKR, MFC, MPW, MWW, NBL, NNN, NYT, ONNN, OZM, PM, PMT, PTEN, S, SBH, SIAL, SNE, SNI, SPH, SQNS, TDC, TEVA, XYL 1 Comment [Earnings]
- Thursday, November 1, 2012, 8:17 AM More on Teva (TEVA) Q3: swings to net loss of $79M from profit of $916M last year, due to $670M provision connected to patent litigation and $481M impairment mostly related to R&D. U.S. sales +33% to $2.6B, boosted by the acquisition of Cephalon. Europe sales +13% in local currencies. Copaxone revenue +13% to $1.05B. Narrows 2012 guidance range to $5.32-$5.38 for EPS and $20.1B-$20.7B for revenue, both in line. 3 Comments [Healthcare, Earnings]
- Thursday, November 1, 2012, 7:10 AM Teva Pharmaceutical Industries (TEVA): Q3 EPS of $1.28 beats by $0.03. Revenue of $4.97B (+14% Y/Y) misses by $100M. (PR) Comment! [Earnings, Healthcare]
- Thursday, November 1, 2012, 12:05 AM Notable earnings before Thursday’s open: ABC, ABX, ADP, ALKS, APA, AVP, BCE, BYD, CI, CNSL, CTRX, CVC, DLPH, DX, EL, EPD, ESV, EXC, FIRE, GAS, GNC, GTLS, HEP, HSH, INCY, ITRI, IVZ, K, LLL, MPC, NGLS, NIHD, OCN, PEG, PFE, PXP, RDN, RGLD, SE, SIRI, SNE, SPR, TDC, TE, TEVA, UPL, UTHR, VNR, WNR, WPI, XOM, XYL Comment! [Earnings]
- Wednesday, October 31, 2012, 5:30 PM Notable earnings before Thursday’s open: ABC, ABX, ADP, ALKS, APA, AVP, BCE, BYD, CI, CNSL, CTRX, CVC, DLPH, DX, EL, EPD, ESV, EXC, FIRE, GAS, GNC, GTLS, HEP, HSH, INCY, ITRI, IVZ, K, LLL, MPC, NGLS, NIHD, OCN, PEG, PFE, PXP, RDN, RGLD, SE, SIRI, SNE, SPR, TDC, TE, TEVA, UPL, UTHR, VNR, WNR, WPI, XOM, XYL Comment! [Earnings]
- Thursday, August 2, 2012, 8:03 AM More on Teva (TEVA +0.1%) Q2: net profit rises to $863M from $576M, due to the launch of four new generic drugs in the U.S. and an increase in sales of branded treatments. Affirms FY outlook for adjusted EPS of $5.30-$5.40 vs. consensus of $5.37 and revenue of $20-$21B vs. $20.58B. U.S. sales +28% to $2.5B, European sales unchanged at $1.5B. Comment! [Earnings, Healthcare]
- Thursday, August 2, 2012, 7:08 AM Teva Pharmaceutical Industries (TEVA): Q2 EPS of $1.28 in-line. Revenue of $5.0B (+19% Y/Y) misses by $80M. (PR) 3 Comments [Earnings, Healthcare]
- Thursday, August 2, 2012, 12:05 AM Notable earnings before Thursday’s open: AEE, APA, ARIA, BDX, CAH, CI, CNP, DNR, DTV, DUK, ENB, GM, INCY, K, MFA, NNN, OCN, PGN, PH, PRX, PWR, PXP, RDC, SBH, SE, SEE, SHO, SNE, SRE, TDC, TE, TEVA, TIE, TWC, UPL, VIAB, VRX, WNR, XEL Comment! [Earnings]
- Wednesday, August 1, 2012, 5:30 PM Notable earnings before Thursday’s open: AEE, APA, ARIA, BDX, CAH, CI, CNP, DNR, DTV, DUK, ENB, GM, INCY, K, MFA, NNN, OCN, PGN, PH, PRX, PWR, PXP, RDC, SBH, SE, SEE, SHO, SNE, SRE, TDC, TE, TEVA, TIE, TWC, UPL, VIAB, VRX, WNR, XEL Comment! [Earnings]
- Thursday, May 24, 2012, 9:05 AM More on Teva (TEVA) 2012 guidance: The EPS of forecast of $5.30-$5.40 is below prior guidance of $5.48-$5.68; revenue prediction of $20B-$21B is below $22B prior. Teva's Europe outlook has been affected by over $1B. If there are businesses that don't fit, "we'll be looking to divest," says CEO Jeremy Levin. 2 Comments [Earnings, Healthcare]
- Thursday, May 24, 2012, 8:58 AM Teva (TEVA) provides 2012 guidance on a conference call to investors, saying it expects EPS of $5.30-$5.40 vs. consensus of $5.59. It forecasts net revenue of $20B-$21B vs. 21.27B. Breakdown: U.S. $10.5B, Europe $5.8B, ROW $4.2B, Copaxone $3.8B. Shares +1.4% premarket. (PR) 2 Comments [Earnings, Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Steffen Jørgensen
I just published an interesting article about $TEVA - A company in the pharmaceutical industry with low valuation and remarkable growth - View all 4 replies
-
onneke: be carefull, with teva , the goodwill is too high, if one deducts same, p/b ratio is 8....!! -
Steffen Jørgensen: and why do you think their goodwill is too high? What do you base your conclusion on?
-
Steffen Jørgensen
How much will $TEVA fall before the rebound starts? The current price has strong historical TA support. Fundamentals are strong as well - View all 0 replies
-
Dividend Sheet
$AZN $GSK $MRK are the best yielding heathcare stocks with a lower volatility than the market - http://stks.co/cP2U - $JNJ $TEVA - View all 0 replies
-
Contextuall
Media Sentiment on Teva Pharmaceutical Industries Limited $TEVA: 21.74% positive, 11.59% negative, 66.67% neutral http://bit.ly/ZXSUZR - View all 0 replies
-
- View all 6 replies
-
-
Steffen Jørgensen: Agree TDune75, but Teva is a long-term inv. due to growth in dividend, revenues and EPS. The domegraphic conditions looks good as well.
-
- View all 2 replies
-
charlot-97: I'll enjoy any uptrend in $TEVA that lasts longer than 15 minutes. Disclosure: Long $TEVA, sometimes unsure why. -
-
Retail Investor
$DNDN $AMRN $TEVA $ARNA $CLSN $SPY $TARO Posts Strong Results -> http://bit.ly/THNRyQ - View all 0 replies
LATEST REPLIES
-
Steffen Jørgensen
I just published an interesting article about $TEVA - A company in the pharmaceutical industry with low valuation and remarkable growth - View all 4 replies
-
onneke: be carefull, with teva , the goodwill is too high, if one deducts same, p/b ratio is 8....!!
-
Steffen Jørgensen: and why do you think their goodwill is too high? What do you base your conclusion on?
-
- View all 6 replies
-
-
Steffen Jørgensen: Agree TDune75, but Teva is a long-term inv. due to growth in dividend, revenues and EPS. The domegraphic conditions looks good as well.
-
- View all 2 replies
-
charlot-97: I'll enjoy any uptrend in $TEVA that lasts longer than 15 minutes. Disclosure: Long $TEVA, sometimes unsure why.
-
-
neobliviscar
$TEVA- closing personal position. Sold 40 Jan $37.5 puts for about 0.75 & buying back at 0.05. I know one or two others were in with me. - View all 2 replies
-
-
SKS1586: Awesome. I entered around same time by selling Jan14 50Puts (longer horizon & dividend collection). Your strategy looks better now.
-
- View all 4 replies
-
VFC's Stock House: Haha, SmokeyRose - I don't know much more than anyone else, except that $INO is up about twenty five percent this year. Nice. Good luck!
-
-
- View all 7 replies
-
-
Julius Ferraro: Sold some 37.5 puts. Nothing in this market is cheap anymore
-
neobliviscar
$TEVA . Had to wait for this one to bottom. Selling Jan Puts at this level. Be happy to go long here & conv to Cov Call later. - View all 5 replies
-
chopchop0: I decided to bite on a long position today. Seems insanely cheap at 7x forward earnings.
-
neobliviscar: P/E can be dang w/ drug co., but reviewing what they've got & the likelyhood of 'will have', seemed very safe risk/reward $35-$37.5 buy zone
-
Energysystems
Nice bounces for $MMLP, $KRFT, and $FCX. $TEVA is taking a big hit though...my only loser in my portfolio - View all 5 replies
-
Ocean Man: MMLP up 2% and absolutely no weakness as the market dropped late in the day.
-
-
Energysystems
Nice to see $AFL finally making me some $$. Now only one negative position in my portfolio($TEVA). - View all 1 replies
-
-
1980XLS-2.0
TEVA. It appears the banksters that bought tens of thousands of Oct $42.50 calls a week or two ago, plan on not being denied. - View all 5 replies
-
1980XLS-2.0: I played it mostly with stock, got out yeasterday,with modest gains, thanks to filling position incrementally.Somebody lost big.
-
FortSumter: Turns out they were expecting an FDA approval which came yesterday.....oops, a little late. haha
-
- View all 8 replies
-
-
FortSumter: Quick math shows 26K @100 shares per to tie up almost 3% of the available shares for a one day event. Hmmmmm.
-
- View all 3 replies
-
-
-
Saibus Research
Teva: Undervalued Industry Leading Generic Drug Maker At 7.5X Adjusted EPS http://seekingalpha.com/a/gx39 $TEVA - View all 2 replies
-
Mercy Jimenez: Agree but watch entry price; testing results, Israeli/ Iran jitters etc.have swung to $35 recently; I add as it hits $37-39 during meltdowns -
Saibus Research: Mercy, not a bad entry point. Healthcare sector undervalued relative to its historical multiples and has held up well in the last few months
-
Daniel Shvartsman
$TEVA wins Copaxone trial, up almost 7% AH. I'm bummed it never dropped to my limit orders at 37.5. Weird to drop good news late on Friday. - View all 1 replies
-
Energysystems: Hopefully it'll continue up a bit, looking to lighten up my position.
-
Mercy Jimenez
Sold back out TEVA addition from Fri; premarket action @$38 + continued high selling ratio does not look healthy; will add back on drops. - View all 6 replies
-
-